Lindsay Nelson

Lindsay Nelson supports the procurement mission of the National Cancer Institute by managing complex acquisitions critical to advancing cancer research and diagnostic innovation. Though their formal title is not listed, their role involves overseeing the solicitation, evaluation, and award of contracts for high-precision scientific equipment, laboratory services, and computational infrastructure essential to NIH’s biomedical research pipeline. They handle a diverse portfolio of acquisitions aligned with the Institute’s strategic priorities in precision medicine, translational science, and data-driven oncology, ensuring compliance with federal acquisition regulations while enabling rapid deployment of cutting-edge capabilities to researchers across the nation. Nelson maintains a consistent working relationship with Quality Biological, Inc., a key supplier of biological reagents and specialized research materials essential for preclinical and clinical cancer studies. This long-standing vendor partnership reflects a focus on reliable, high-purity biospecimen sourcing and analytical support services. Their contracting patterns indicate a preference for established vendors with proven expertise in life science supply chains, while still maintaining open channels for competitive bidding and technical evaluation. Set-aside preferences reveal a strong emphasis on open competition, with 85.7% of awards issued without socioeconomic set-asides, and only 14.3% designated as total small business set-asides under FAR 19.5. This pattern suggests a procurement strategy prioritizing technical capability and scientific rigor over socioeconomic criteria, though small business participation remains a recognized component of their acquisition portfolio. Nelson’s contracting focus centers on NAICS 541380 (Testing Laboratories and Services), reflecting heavy demand for clinical trial support and biomarker analysis. Additional emphasis is placed on NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and 339112 (Surgical and Medical Instrument Manufacturing), indicating procurement of next-generation sequencing platforms, flow cytometers, and precision surgical tools. They also support computing infrastructure under NAICS 518210 and data storage systems under NAICS 334112, underscoring expertise in integrating laboratory automation with high-performance data environments for cancer genomics and AI-driven research.